Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
By: Jinlv Qin, Guizuo Wang and Dong Han
References
- Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019; 53(1). DOI: 10.1183/13993003.01913-2018
- Qin J, Wang G, Han D. Selexipag in patients with pulmonary hypertension: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2023; 48(2): 101466. DOI: 10.1016/j.cpcardiol.2022.101466
- Mandras SA, Mehta HS, Vaidya A. Pulmonary hypertension: a brief guide for clinicians. Mayo Clin Proc. 2020; 95(9): 1978–1988. DOI: 10.1016/j.mayocp.2020.04.039
- Pahal P, Sharma S. Idiopathic pulmonary artery hypertension. In: StatPearls. Treasure Island, FL: StatPearls Publishing LLC; 2022.
- Wang G, Shang W, Ren Y, Liu S, Ren X, Wei S, et al. Benefits of statins in chronic obstructive pulmonary disease patients with pulmonary hypertension: A meta-analysis. Eur J Intern Med. 2019; 70: 39–42. DOI: 10.1016/j.ejim.2019.09.009
- Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012; 7(10):
e47662 . DOI: 10.1371/journal.pone.0047662 - Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem. 2012; 55(17): 7849–61. DOI: 10.1021/jm3009103
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4): 264–9. DOI: 10.7326/0003-4819-151-4-200908180-00135
- Detsky AS, Naylor CD, O’Rourke K, McGeer AJ, L’Abbé KA. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol. 1992; 45(3): 255–65. DOI: 10.1016/0895-4356(92)90085-2
- Shang W, Zhang Y, Wang G, Han D. Anakinra was not associated with lower mortality in hospitalised COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Rev Med Virol. 2023; 33(2):
e2418 . DOI: 10.1002/rmv.2418 - Shang W, Wang Y, Wang G, Han D. Benefits of ozone on mortality in patients with COVID-19: A systematic review and meta-analysis. Complement Ther Med. 2023; 72: 102907. DOI: 10.1016/j.ctim.2022.102907
- Ren Y, Wang G, Han D. Statins in hospitalized COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. J Med Virol. 2023; 95(6):
e28823 . DOI: 10.1002/jmv.28823 - Wang G, Qin J, Han D. Long-term safety of macitentan in patients with pulmonary hypertension: A meta-analysis of randomised controlled trials. Eur J Clin Invest. 2023:
e14059 . DOI: 10.1111/eci.14059 - Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928. DOI: 10.1136/bmj.d5928
- Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, et al. Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation. 2019; 139(1): 51–63. DOI: 10.1161/CIRCULATIONAHA.118.033575
- Ghofrani HA, Simonneau G, D’Armini AM, Fedullo P, Howard LS, Jaïs X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT–1): Results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017; 5(10): 785–794. DOI: 10.1016/S2213-2600(17)30305-3
- Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369(9): 809–18. DOI: 10.1056/NEJMoa1213917
- Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, et al. SERAPHIN haemodynamic substudy: The effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017; 38(15): 1147–1155. DOI: 10.1093/eurheartj/ehx025
- Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019; 7(7): 594–604. DOI: 10.1016/S2213-2600(19)30091-8
- Vachiéry JL, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018; 51(2). DOI: 10.1183/13993003.01886-2017
- Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016; 4(4): 306–22. DOI: 10.1016/S2213-2600(15)00543-3
- Rose-Jones LJ, McLaughlin VV. Pulmonary hypertension: Types and treatments. Curr Cardiol Rev. 2015; 11(1): 73–9. DOI: 10.2174/1573403X09666131117164122
- Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019; 53(1). DOI: 10.1183/13993003.01889-2018
- Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016; 37(12): 942–54. DOI: 10.1093/eurheartj/ehv512
- Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992; 85(2): 504–9. DOI: 10.1161/01.CIR.85.2.504
- Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J. 1997; 18(2): 254–8. DOI: 10.1093/oxfordjournals.eurheartj.a015228
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151(4): W65–94. DOI: 10.7326/0003-4819-151-4-200908180-00136
- Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation (SOPRANO). NCT02554903 trial. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT02554903 . Accessed November 3, 2022.
DOI: https://doi.org/10.5334/gh.1274 | Journal eISSN: 2211-8179
Language: English
Submitted on: Jun 1, 2023
Accepted on: Oct 5, 2023
Published on: Oct 26, 2023
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2023 Jinlv Qin, Guizuo Wang, Dong Han, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.